Patent intelligence · EP
EP 2222277
PEGYLIERTE LIPOSOMALE FORMULIERUNGEN ZUR PHOTODYNAMISCHEN BEHANDLUNG VON ENTZÜNDLICHEN ERKRANKUNGEN
PEGYLIERTE LIPOSOMALE FORMULIERUNGEN ZUR PHOTODYNAMISCHEN BEHANDLUNG VON ENTZÜNDLICHEN ERKRANKUNGEN
Patent details — EP 2222277
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Sep 1, 2010
- Expiration
- Aug 27, 2030
- Applicant
- CERAMOPTEC GMBH [DE]
- CPC classes
- A61K 9/ 127 A I, A61K 41/ 00 A I, A61K 47/ 48 A I, A61K/410071
Quick answer
EP 2222277 (PEGYLIERTE LIPOSOMALE FORMULIERUNGEN ZUR PHOTODYNAMISCHEN BEHANDLUNG VON ENTZÜNDLICHEN ERKRANKUNGEN) is held by CERAMOPTEC GMBH [DE]. Status: granted. Granted Sep 1, 2010. Expires Aug 27, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CERAMOPTEC GMBH [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 127 A I, A61K 41/ 00 A I, A61K 47/ 48 A I, A61K/410071, A61K/476911, A61K/91271
More from CERAMOPTEC GMBH [DE]
Related pharmaceutical patents in our USPTO index.
-
BR PI0714667
conjugado molecular e respectivo uso
granted -
MX 2013000877
APPLICATION OF β-FUNCTIONALIZED DIHYDROXY-CHLORINS FOR PDT.
granted -
US 2013041307
APPLICATION OF BETA-FUNCTIONALIZED DIHYDROXY-CHLORINS FOR PDT
granted -
WO 2013015774
DIHYDROXY-CHLORINES GLYCO-SUBSTITUÉES ET CHLORINES BÊTA-FONCTIONNALISÉES POUR THÉRAPIE ANTIMICROBIENNE PHOTODYNAMIQUE
granted -
BR PI0614453
método de redução de cululite indesejada em áreas seletivas de um organismo e mistura fotossensibilizante
granted -
US 2012263625
GLYCO-SUBSTITUTED DIHYDROXY-CHLORINS AND ß-FUNCTIONALIZED CHLORINS FOR ANTI-MICROBIAL PHOTODYNAMIC THERAPY
granted -
US 2012259187
DYNAMIC COLORECTAL PDT APPLICATION
granted -
US 2011206613
METHOD AND APPLICATION OF UNSYMMETRICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT
granted
Frequently asked questions
What is US patent 2222277?
EP 2222277 (PEGYLIERTE LIPOSOMALE FORMULIERUNGEN ZUR PHOTODYNAMISCHEN BEHANDLUNG VON ENTZÜNDLICHEN ERKRANKUNGEN) is held by CERAMOPTEC GMBH [DE]. Status: granted. Granted Sep 1, 2010. Expires Aug 27, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 2222277?
CERAMOPTEC GMBH [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does EP 2222277 expire?
Our index shows an expiration date of Aug 27, 2030 (4 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.